Objectives: To investigate whether perioperative Sonoclot analyses could identify differences in hemostatic function between a group of patients with unstable coronary artery disease treated with low-molecular-weight heparin until the evening before surgery and a group of patients with stable coronary artery disease not treated with low-molecular-weight heparin.
Design: Prospective and observational investigation.
Setting: A university hospital, single institution.
Participants: Patients scheduled for coronary artery bypass surgery.
Interventions: Blood samples for Sonoclot analysis were drawn preoperatively, 5 minutes after the administration of heparin, immediately after and 20 minutes after cardiopulmonary bypass was established, and 30 minutes and 3 and 20 hours after the end of surgery in a group of patients with unstable coronary artery disease and a group of patients with stable coronary artery disease.
Measurements And Main Results: The Sonoclot variables sonACT, coagulation rate, time to peak, amplitude of the peak, and R3 were recorded. The sonACT was significantly lower in the enoxaparin group compared with the control group, whereas the coagulation rate was significantly higher in the enoxaparin group. There were no statistically significant differences in time to peak, amplitude of the peak, and R3 between the 2 study groups.
Conclusions: The presence of a hypercoagulable state in patients with unstable coronary artery disease is indicated by the significantly higher coagulation rate observed in this group compared with the control group. Further larger studies are needed for evaluation of the usefulness of Sonoclot analysis in the monitoring of hemostatic function in patients with unstable coronary artery disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1053/j.jvca.2007.12.024 | DOI Listing |
Curr Atheroscler Rep
January 2025
Department of Medicine, Division of Cardiology, University of California, Los Angeles, Los Angeles, CA, USA.
Purpose Of Review: Discuss the relationship between pregnancy complications and long-term atherosclerotic cardiovascular disease (ASCVD) risk.
Recent Findings: A large body of research confirms an association between pregnancy complications and increased short and long-term ASCVD risk and seeks to understand mechanisms for these associations. Social determinants of health continue to have a critical impact on the prevalence of adverse pregnancy outcomes (APOs) and long term ASCVD risk.
Neth Heart J
January 2025
Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands.
Objectives: Coronary graft failure (CGF) may occur early after coronary bypass graft surgery (CABG). The study aimed to identify clinical and perioperative risk factors and to evaluate the long-term clinical impact of symptomatic early CGF.
Methods: Patients who underwent clinically indicated coronary angiography (CAG) prior to post-CABG discharge between 2012 and 2022 were included.
Curr Cardiol Rep
January 2025
Division of Rheumatology, Department of Internal Medicine, Texas Tech Health Sciences Center El Paso, Paul L. Foster School of Medicine, El Paso, TX, USA.
Purpose Of Review: To highlight advancements in managing traditional and rheumatoid arthritis (RA) specific risk factors and the impact of RA treatments on cardiovascular outcomes.
Recent Findings: Advancements in rheumatoid arthritis management have paralleled declining trends in cardiovascular disease risks. Biomarkers like CRP, Lipoprotein(a), Apolipoprotein B 100, and imaging tools such as coronary artery calcium scoring enhance cardiovascular risk stratification, particularly in intermediate-risk RA patients.
Biogerontology
January 2025
Center for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.
The growing prevalence of age-related cardiovascular diseases (CVDs) poses significant health challenges, necessitating the formulation of novel treatment approaches. GATA4, a vital transcription factor identified for modulating cardiovascular biology and cellular senescence, is recognized for its critical involvement in CVD pathogenesis. This review collected relevant studies from PubMed, Google Scholar, and Science Direct using search terms like 'GATA4,' 'cellular senescence,' 'coronary artery diseases,' 'hypertension,' 'heart failure,' 'arrhythmias,' 'congenital heart diseases,' 'cardiomyopathy,' and 'cardiovascular disease.
View Article and Find Full Text PDFEur Heart J
January 2025
School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 2199 Lishui Rd, Nanshan, Shenzhen, Guangdong Province 518055, China.
Background And Aims: Lackluster results from recently completed gene therapy clinical trials of VEGF-A delivered by viral vectors have heightened the need to develop alternative delivery strategies. This study aims to demonstrate the pre-clinical efficacy and safety of extracellular vesicles (EVs) loaded with VEGF-A mRNA for the treatment of ischaemic vascular disease.
Methods: After encapsulation of full-length VEGF-A mRNA into fibroblast-derived EVs via cellular nanoporation (CNP), collected VEGF-A EVs were delivered into mouse models of ischaemic injury.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!